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Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors have vasoprotective effects. This study investigated
whether a recently approved DPP-4 inhibitor, linagliptin (Lina), suppresses atherogenesis in non-diabetic
apolipoprotein-E deﬁcient (ApoE−/−) mice, and examined its effects on endothelial function.
Methods and results: Lina (10 mg/kg/day) was administered orally to ApoE−/−mice for 20 weeks. Lina reduced
atherogenesis without alteration of metabolic parameters including blood glucose level compared with control
(P b 0.05). Results of immunohistochemical analyses and quantitative RT-PCR demonstrated that Lina signiﬁ-
cantly decreased inﬂammatory molecule expression and macrophage inﬁltration in the atherosclerotic aorta.
Lina administration to ApoE−/−mice for 9 weeks ameliorated endothelium-dependent vasodilation compared
with that in untreated mice. Plasma active glucagon-like peptide-1 (GLP-1) level was signiﬁcantly higher in
the treated group (P b 0.05). Exendin-4 (Ex-4), a GLP-1 analog, ameliorated endothelium-dependent vasodila-
tion impaired by palmitic acid (PA) in wild-type mouse aortic segments. Ex-4 promoted phosphorylation of
eNOSSer1177 and Akt, both of whichwere abrogated by PA, in human umbilical vein endothelial cells. In addition,
Lina administration to ApoE−/−mice decreased oxidative stress, as determined by urinary 8-OHdG secretion and
NADPH oxidase subunit expression in the abdominal aorta.
Conclusion: Lina inhibited atherogenesis in non-diabetic ApoE−/−mice. Amelioration of endothelial dysfunction
associated with a reduction of oxidative stress by GLP-1 contributes to the atheroprotective effects of Lina.© 2015 Elsevier Inc. All rights reserved.1. Introduction
Chronic inﬂammation plays a central role in the pathogenesis of
atherosclerosis [1]. Endothelial dysfunction caused by cardiovascular
risk factors is a key initiator of vascular inﬂammation [2]. Dysfunctionliptin; ApoE−/−, apolipoprotein-
din-4; PA, palmitic acid; WTD,
, 8-hydroxy-2′-deoxyguanosine;
1, vascular cellular adhesion
line; SNP, sodium nitroprusside;
cular endothelial growth factor;
cies.
ascular Medicine, Institute of
chool, 3-18-15 Kuramoto-cho,
kuda).of endothelial cells alters vascular responses and induces the expression
of adhesion molecules and chemokines which stimulate monocyte-
endothelial cell interaction, leading to the development of atherosclero-
sis [3]. Therefore, abrogation of endothelial dysfunction is an attractive
strategy for preventing vascular inﬂammation and atherosclerosis.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antidi-
abetic drugs that improve glucosemetabolism by raising the active con-
centration and duration of action of glucose-like peptide (GLP)-1, a gut
hormone secreted in response to nutrient ingestion that stimulates
glucose-dependent insulin secretion [4]. In addition to their anti-
diabetic property, recent studies have suggested that DPP-4 inhibitors
have anti-inﬂammatory effects independent of their glucose-lowering
effect [5–9]. The GLP-1 receptor mediates major function of GLP-1. The
GLP-1 receptor is known to be expressed in pancreatic β cells, although
recent studies demonstrated its expression in endothelial cells, suggest-
ing vasoprotective effects independent of blood glucose level [10,11].
Table 1
Effects of Lina on metabolic parameters after 20-week treatment.
Ctrl (N = 14) Lina (N = 16) P-value
Body weight, g 37.3 ± 2.0 34.2 ± 2.2 0.33
Blood glucose, mg/dL 92.9± 6.2 99.5± 6.0 0.45
Insulin, ng/mL 4.8± 0.7 4.2± 0.8 0.57
Total cholesterol, mg/dL 690.0 ± 49.8 554.6 ± 72.6 0.15
Triglyceride, mg/dL 73.5 ± 5.3 84.8 ± 10.8 0.39
HDL cholesterol, mg/dL 12.5 ± 1.3 11.5 ± 1.8 0.67
Heart rate, bpm 680.0 ± 20.8 687.7 ± 24.8 0.83
Systolic BP, mm Hg 97.7 ± 3.6 93.0 ± 1.5 0.19
Diastolic BP, mm Hg 74.1 ± 3.9 67.4 ± 2.1 0.12
BP; blood pressure, Ctrl; control, Lina; linagliptin. All values are mean ± SEM.
17H.M. Salim et al. / Vascular Pharmacology 79 (2016) 16–23Previously, we have reported that the GLP-1 analog, exendin-4 (Ex-4),
attenuated neointima formation after mechanical vascular injury by
inhibiting macrophage activation at least partially in normoglycemic
mice [12]. Also several studies have demonstrated that DPP-4 inhibitors
suppressed the development of atherosclerosis even in non-diabetic
atheroscleroticmodels [13–16]. However, the effects of DPP-4 inhibitors
on endothelial cell function, associated with atherogenesis, in normo-
glycemic animals have not been fully investigated. Therefore, in this
study, we administered linagliptin (Lina), whichwas recently approved
as an oral glucose-lowering drug [17], to normoglycemic apolipoprotein
E-deﬁcient (ApoE−/−) mice and examined the effects of Lina on endo-
thelial cell function and atherogenesis. Our ﬁndings demonstrated that
Lina reduced the development of atherosclerosis and ameliorated endo-
thelial dysfunction in this mouse model. Results of in vitro and ex vivo
experiments suggested that the antioxidant effect of GLP-1 contributed,
at least partially, to these results.2. Materials and methods
2.1. Animals and drug administration
ApoE−/− (C57BL/6J background) mice were originally purchased
from The Jackson Laboratory. The ApoE−/− mouse, which exhibits
severe hypercholesterolemia, is a widely used mouse model of athero-
sclerosis [18]. All experimental procedures conformed to the guidelines
for animal experimentation of Tokushima University. Linawas supplied
by Boehringer Ingelheim, Japan. To examine the effect of Lina on athero-
genesis, 8-week-old male ApoE−/−mice receiving a western-type diet
(WTD) were treated with Lina 10 mg/kg/day by gavage for 20 weeks.
To examine the effect of Lina on endothelial function at earlier stage of
atherosclerosis, the same dose of Lina was administered to 7-week-old
female ApoE−/− for 9 weeks. WTD was started from 8 weeks of age.
Lina was suspended in 0.5% carboxymethyl cellulose (CMC) solution.
The control group received an equivalent volume of CMC. Mice were
maintained under a 12 h light/dark cycle.Fig. 1. Effect of Lina on atherosclerotic lesion progression innormoglycemic ApoE−/−mice.
En face Sudan IV staining of the aortic arch showed that Lina administration for 20 weeks
signiﬁcantly reduced the progression of atherosclerotic lesions compared with vehicle
(n = 12, per group). Bar: 1 mm. **; P b 0.01. All values are mean ± SEM.2.2. Blood pressure and laboratory data
The blood pressure of each mouse was measured by a tail-cuff sys-
tem (BP-98A, Softron) as described previously. At the time of sacriﬁce,
blood was collected from the heart into EDTA-containing tubes. After
blood samples were centrifuged, plasmawas stored at−80 °C until re-
quired. Plasma total cholesterol, HDL-cholesterol, and triglyceride levels
were measured at LSI Medience Corporation (Japan). Plasma levels of in-
sulin and active GLP-1 were measured using commercially available kits
(Shibayagi Co., Ltd. and Immuno-Biological Laboratories Co., Ltd., respec-
tively). Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) concentration
in a 16 h urine collection was determined using a commercially available
kit (Japan Institute for the Control of Aging, Nikken SEIL Co., Ltd.) and
corrected by creatinine level.2.3. Quantiﬁcation of atherosclerotic lesions
The severity of atherosclerotic lesions in the aortas was assessed as
previously described [19]. In brief, mice were sacriﬁced with an over-
dose of pentobarbital, and perfused with 0.9% sodium chloride solution
at a constant pressure via the left ventricle. Both the heart and whole
aorta were immediately removed. The thoracic aorta was excised,
opened longitudinally, and ﬁxed with 4% paraformaldehyde. To quanti-
fy atherosclerotic lesions in the aortic arch, we performed en face Sudan
IV staining. The percentage of Sudan IV-positive areawasmeasured. The
abdominal aorta was removed and snap-frozen in liquid nitrogen for
gene expression analysis.2.4. Histological and immunohistochemical analyses
Frozen sections of the aortic root (at 5-μm intervals) were obtained
as described previously [19]. The sectionswere stainedwith Oil red O to
detect lipid deposition. Monocyte chemoattractant protein-1 (MCP-1),
vascular cellular adhesion molecule-1 (VCAM-1), and macrophage
antigen-3 (Mac-3) expression were detected using an anti-MCP-1 (BD
Pharmingen), anti-VCAM-1 (Abcam) or anti-Mac3 (BD Biosciences) an-
tibody followed by the avidin–biotin complex technique and stained
using a Vector Red substrate kit (Vector). Each section was counter-
stained with hematoxylin.
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Analysis of vascular reactivity was performed as described previous-
ly [20]. In brief, the descending thoracic aortas frommice were cut into
2-mm rings with special care to preserve the endothelium, and
mounted in organ baths ﬁlled with modiﬁed Krebs–Henseleit buffer
(KHB; 118.4 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4,
1.2 mM MgSO4, 25 mM NaHCO3, 11.1 mM glucose) aerated with 95%
O2 and 5% CO2 at 37 °C. The preparationswere attached to a force trans-
ducer, and isometric tension was recorded on a polygraph. Vessel rings
were primed with 31.4 mM KCl, and then pre-contracted with phenyl-
ephrine, producing submaximal (60% of maximum) contraction.
After the plateau was attained, the rings were exposed to increasingFig. 2. Effect of Lina on characteristics of atherosclerotic plaques. (A) Representative Oil red
C) Representative MCP-1 and VCAM-1 staining of atherosclerotic plaques. Lina signiﬁcan
(D) Representative Mac3 staining of atherosclerotic plaques. Lina tended to decrease macroph
are mean ± SEM.concentrations of acetylcholine (Ach; 10−9 to 10−4 M) and sodium ni-
troprusside (SNP; 10−9 to 10−4 M) to obtain cumulative concentra-
tion–response curves. In some experiments, aortic segments were
incubated with 200 μM palmitic acid (PA, Chem Service) in the pres-
ence/absence of Ex-4 for 4 h before analysis of vascular reactivity.2.6. Cell culture
Human umbilical vein endothelial cells (HUVEC) were purchased
from Life Technologies and cultured in EGM-2 (Lonza). HUVEC (pas-
sages 4–6) were treated with 1 or 10 nM Ex-4 (Sigma-Aldrich) in
EBM-2 (Lonza). For inﬂammatory activation, cells were stimulatedO staining of aortic root. Lina signiﬁcantly decreased lipid deposition in plaques. (B and
tly reduced the expression of MCP-1 (B) and VCAM-1 (C) in atherosclerotic lesions.
age accumulation in plaques. (n = 11–12, per group). Bar: 100 μm. *; P b 0.05. All values
Fig. 3. Effect of Lina on expression of inﬂammatory molecules in abdominal aorta.
(A) Results of qPCR demonstrated that Lina administration reduced RNA expression of
VCAM-1 and MCP-1 in atherosclerotic aorta. Lina also decreased the expression of F4/80,
suggesting reduction of macrophage accumulation in atherosclerotic aorta. (B) Results
of qPCR demonstrated that Lina administration reduced RNA expression of NADPH
oxidase subunits, p47phox and Nox2, in atherosclerotic aorta. (n = 12, per group).
*; P b 0.05. All values are mean ± SEM.
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by vascular endothelial growth factor (VEGF; 10 ng/mL) for 5 min.
2.7. Western blot analysis
Cell lysates were prepared using RIPA buffer (Wako Pure Chemical
Industries, Ltd.) containing a protease inhibitor cocktail (Takara Bio
Inc.) and phosphatase inhibitors. Proteins were separated by SDS-
PAGE and transferred onto polyvinilidine diﬂuoride membranes
(Hybond-P; GE Healthcare). After blocking with 5% bovine serum albu-
min, the membranes were incubated with primary antibody against
either phosphorylated-eNOSSer1177, Akt, phosphorylated-Aktser473 (Cell
Signaling Technology), eNOS (BD Biosciences), or β-actin (Sigma) over-
night at 4 °C. Horseradish peroxidase-conjugated anti-mouse Ig (Cell
Signaling Technology) or anti-rabbit Ig (Chemicon) antibody was then
used as a secondary antibody. Antibody distribution was visualized
with ECL-plus reagent (GE Healthcare) using a luminescent image ana-
lyzer (LAS-1000, Fuji Film).
2.8. Real-time polymerase chain reaction
Total RNA was extracted from the aorta using an illustra RNAspin
RNA Isolation Kit (GE Healthcare). cDNA was synthesized from 100 ng
of total RNA using a QuantiTect Reverse Transcription kit (Qiagen).
Quantitative real-time PCR (qPCR) was performed on an Mx3000P
(Agilent Technologies) using Power SYBR Green PCR Master Mix
(Applied Biosystems). Mouse PCR primers were as follows: F4/80,
sense 5′-TGCATCTAGCAATGGACAGC-3′ and antisense 5′-GCCTTCTGGA
TCCATTTGAA-3′; VCAM-1, sense 5′-CCCGTCATTGAGGATATTGG-3′ and
antisense 5′-GGTCATTGTCACAGCACCAC-3′; MCP-1, sense 5′-CCACTC
ACCTGCTGCTACTCAT-3′ and antisense 5′-TGGTGATCCTCTTGTAGCTC
TCC-3′; p47Phox, sense 5′-ACCTGTCGGAGAAGGTGGT-3′ and antisense
5′-TAGGTCTGAAGGATGATGGG-3′; Nox2, sense 5′-ACTCCTTGGGTCAG
CACTGG-3′ and antisense 5′-GTTCCTGTCCAGTTGTCTTCG-3′; β-actin,
sense 5′-CCTGAGCGCAAGTACTCT GTGT-3′ and antisense 5′-GCTGAT
CCACATCTGCTGGAA-3′. Human PCR primers were as follows: VCAM-
1, sense 5′-ATGAATTCGAACCCAAACA-3′ and antisense 5′-CCTGGCTC
AAGCATTGTCATA-3′; MCP-1, sense 5′-CCCCAGTCAACCGCTGTTAT-3′
and antisense 5′-AGATCTCCTTGGCCACAATG-3′; GAPDH; sense 5′-
TGGGTGTGAACCATGAGAAG-3′ and antisense 5′-GCTAAGCAGTTGGT
GGTGC-3′. Data are expressed in arbitrary units that were normalized
by β-actin or GAPDH.
2.9. Statistical analysis
All results are expressed as mean ± SEM. Comparison of parameters
between two groupswas performedwith unpaired Student's t-test. Com-
parisons of dose–response curves were made by two-factor repeated-
measures ANOVA, followed by Tukey's post hoc test for comparison
between groups. A value of P b 0.05 was considered signiﬁcant.
3. Results
3.1. Effects of Lina on atherosclerotic lesion progression in ApoE−/−mice
To investigate the effect of Lina on atherogenesis, ApoE−/− mice
were treated with Lina or vehicle for 20 weeks. Administration of Lina
to normoglycemic ApoE−/−mice did not alter metabolic parameters in-
cluding blood glucose level, as shown in Table 1. Lina decreased the de-
velopment of atherosclerotic lesions in the aortic arch as determined by
en face Sudan IV staining compared with control (17.9 ± 1.8 vs. 10.0 ±
1.7%, P b 0.01) (Fig. 1). Oil red O staining demonstrated that Lina de-
creased lipid deposition in plaques in the aortic root (15.2 ± 1.7 vs.
10.2 ± 0.7%, P b 0.05) (Fig. 2A). Immunostaining revealed that Lina
signiﬁcantly reduced the expression of MCP-1 (10.9 ± 2.3 vs. 4.5 ±
1.1%, P b 0.05) and VCAM-1 (7.1 ± 1.1 vs. 3.8 ± 1.1%, P b 0.05) inatherosclerotic plaques (Fig. 2B andC). Lina tended to decrease accumu-
lation of macrophages in plaques as determined by immunostaining
against Mac3 (21.1 ± 2.5 vs. 15.3 ± 1.9%, P = 0.09) (Fig. 2D).
3.2. Lina reduced expression of inﬂammatory molecules in aorta
We also examined the effects of Lina on the expression of inﬂamma-
tory molecules in the atherosclerotic aorta using qPCR. Lina decreased
mRNA expression ofMCP-1 (P=0.06) andVCAM-1 (P b 0.05) in the ab-
dominal aorta comparedwith control (Fig. 3A). Also, the expression of a
macrophage marker, F4/80, in Lina-treated mice was lower than that in
controlmice (Pb 0.05). These resultswere consistentwith the immuno-
histochemical results, and suggested that Lina inhibits the expression of
chemokines and adhesion molecules, leading to attenuated monocyte/
macrophage inﬁltration into the plaque. Furthermore, Lina reduced
the expression of NADPH oxidase subunits, p47phox and Nox2 in athero-
sclerotic aorta (Fig. 3B).
3.3. Lina ameliorated endothelial dysfunction in ApoE−/−mice
Impairment of endothelial function is the initial step in vascular
inﬂammation. Therefore, to investigate the effect of Lina on endothelial
function in a normoglycemic condition, endothelium-dependent vaso-
dilation was examined in wild-type and ApoE−/− mice. Endothelium-
dependent vasodilation in response to Ach was signiﬁcantly impaired in
ApoE−/− mice after 8-week WTD feeding compared with that in age-
sex-matched wild-type mice; however, Lina administration for 9 weeks
Table 2
Effects of Lina on metabolic parameters after 9-week treatment.
Ctrl (N = 12) Lina (N = 12) P-value
Body weight, g 25.6 ± 0.5 24.8 ± 0.5 0.30
Blood glucose, mg/dL 121.0 ± 2.6 116.0 ± 3.9 0.30
Insulin, ng/ml 0.9 ± 0.1 1.1 ± 0.1 0.52
Total cholesterol, mg/dL 881.8 ± 26.7 864.0 ± 37.1 0.71
Triglyceride, mg/dL 45.6 ± 4.2 50.7 ± 5.4 0.47
HDL cholesterol, mg/dL 9.5 ± 0.9 11.9 ± 0.9 0.06
Ctrl; control, Lina; linagliptin. All values are mean ± SEM.
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(Fig. 4A). Metabolic parameters did not differ between vehicle and Lina
treated ApoE−/− mice (Table 2). On the other hand, endothelium-
independent relaxation in response to SNP did not differ between the
Lina and control groups (Fig. 4B). In this experiment, Lina administration
to ApoE−/−mice signiﬁcantly elevated the plasma level of active GLP-1
compared with control (11.8 ± 0.5 vs. 17.7 ± 1.3 pg/mL, P b 0.01), as
shown in Fig. 4C. Furthermore, Lina administration signiﬁcantly de-
creased urinary excretion of 8-OHdG in ApoE−/− mice compared to
control (Fig. 4D).3.4. Ex-4, a GLP-1 analog, attenuated endothelial dysfunction caused by PA
To investigate whether increased GLP-1 level is associated with
improvement of endothelial function, endothelium-dependent vasodi-
lation was examined using aortic rings obtained from wild-type mice.
Ex-4, a GLP-1 analog, signiﬁcantly improved vasodilation in response
to Ach, which was impaired by incubation with PA, a common free
fatty acid found in hyperlipidemic animals (Fig. 5A). Ex-4 did not affect
endothelium-independent relaxation in response to SNP (Fig. 5B). We
further investigated the molecular mechanism by which Ex-4 attenuat-
ed impaired endothelium-dependent vasodilation induced by PA.
Results of western blotting demonstrated that Ex-4 signiﬁcantly promot-
ed phosphorylation of Akt and eNOSSer1177, which were reduced in the
presence of PA in HUVECs (Fig. 5C). In addition, we examined
whether GLP-1 attenuated the expression of inﬂammatory mole-
cules related to monocyte/macrophage recruitment in endothelialFig. 4. Lina improved endothelial function in normoglycemic ApoE−/−mice. (A and B) Vascular
ministered ApoE−/−mice and age-sex-matched WT mice. Lina administration for 9 weeks am
ApoE−/−mice at earlier stage of atherosclerosis (A). Vasorelaxation in response to SNP (B) di
compared with CMC group. (C) Lina administration signiﬁcantly increased plasma level of acti
of 8-OHdG in ApoE−/−mice. (n = 5–7, per group). *; P b 0.05 and **; P b 0.01. Data representcells. Ex-4 signiﬁcantly attenuated the expression of VCAM-1 and MCP-
1 in HUVECs treated with PA (Fig. 6A and B).
4. Discussion
Previous studies have reported that DPP-4 inhibitors reduced the de-
velopment of atherosclerosis in both hyperglycemic and normoglycemic
atherosclerosis models by inhibiting vascular inﬂammation [21]. Most of
those studies have demonstrated that DPP-4 inhibitors reduce vascular
inﬂammation via suppression of pro-inﬂammatory activation of mono-
cytes/macrophages independent of blood glucose level [22–24]. Endothe-
lial dysfunction, as well as inﬂammatory cell activation, is a pivotal factor
for the initiation of atherogenesis [25]. Therefore, in this study,we focused
on the effect of a DPP-4 inhibitor on endothelial function associated with
the development of atherosclerosis in ApoE−/−mice. Corresponding to
the previous studies, we demonstrated that Lina reduced atherosclerotic
lesion progression and the expression of inﬂammatory molecules in thereactivity to Ach or SNP was determined using aortic rings isolated from Lina- or CMC-ad-
eliorated endothelium-dependent vasodilation in response to Ach compared with CMC in
d not differ among the three groups. (n = 10–12, per group) *; P b 0.05 and **; P b 0.01
ve GLP-1 in ApoE−/−mice. (D) Lina administration signiﬁcantly decreased urine secretion
mean ± SEM.
Fig. 5. Ex-4 attenuated endothelial dysfunction induced by PA. (A and B) To investigate the effects of Ex-4, a GLP-1 analog, on endothelial function, vascular reactivity to Ach or SNP was
examined using aortic rings isolated fromWT mice. Aortic rings were incubated with PA (200 μM) in the presence or absence of Ex-4 for 4 h. Ex-4 signiﬁcantly improved endothelium-
dependent vasodilation impaired by PA (A). On the other hand, EX-4 did not affect endothelium-independent vasodilation (B) (n= 8–9, per group). (C) To investigate the effects of Ex-4
on endothelial cells, phosphorylation of Aktser473 and eNOSSer1177 in response to VEGF was examined in HUVEC. Results of western blotting demonstrated that Ex-4 promoted the phos-
phorylation of Akt and eNOS, which was impaired in the presence of PA (n = 5–6, per group). *; P b 0.05 and **; P b 0.01 compared with PA. All values are mean ± SEM.
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thermore, our results demonstrated that elevatedGLP-1 level contributed
to the improvement of endothelial function. Reduction of oxidative stress
by Lina administration might have roles in the protection of endothelial
function and in suppression of atherogenesis, at least in part.
It is a widely accepted view that endothelial damage disturbs ho-
meostasis and initiates the atherosclerotic process including endothelial
permeability, platelet aggregation, leukocyte adhesion, and generation
of cytokines [26]. Therefore, endothelial dysfunction is considered to
be an early marker of atherosclerosis and a target for the prevention
of atherosclerosis [3]. Cardiovascular risk factors cause endothelial
dysfunction. Especially, type 2 diabetes associates with endothelialFig. 6. Ex-4 attenuated expression of inﬂammatorymolecules in endothelial cells. (A and B) To i
related tomonocyte/macrophage recruitment in endothelial cells, HUVECswere incubatedwith
ed that Ex-4 signiﬁcantly reduced the expression of VCAM-1 (A) and MCP-1 (B). (n = 4, per gdysfunction, which contributes to the development of its micro- and
macrovascular complications. Reactive oxygen species (ROS) generated
under a hyperglycemic condition play a causal role in endothelial dys-
function in type 2 diabetes [27]. Previous studies demonstrated that
GLP-1 regulates vascular tone and endothelial function [11,28,29]. In
fact, GLP-1-mimetics and DPP-4 inhibitors, including Lina, attenuated
endothelial dysfunction in a hyperglycemic condition through NO
production in human and animal experiments [11,30–35]. Also, several
studies showed that Lina improved vascular function in an LPS-induced
sepsis model [36] and hypertension [37], although few studies have in-
vestigated the effects of Lina on endothelial function, associated with
the development of atherosclerosis in a hyperlipidemic model. Thenvestigate the effects of Ex-4, a GLP-1 analog, on the expression of inﬂammatorymolecules
200 μMPA for 4 h in the presence or absence of Ex-4. Results of qPCR analysis demonstrat-
roup). *; P b 0.05 and **; P b 0.01 compared with PA. All values are mean ± SEM.
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vasodilation was improved in Lina-treated ApoE−/−mice, indicating its
protective effects on endothelial cell function in a hyperlipidemic condi-
tion, one of the major cardiovascular risk factors.
Lina elevated plasma active GLP-1 concentration in ApoE−/−mice.
Therefore, we investigated the effect of GLP-1 on endothelial function.
Our ex vivo experiment using aortic rings obtained fromWTmice dem-
onstrated that Ex-4, a GLP-1 analog, improved endothelium-dependent
vasodilationwhichwas impaired by the presence of PA, one of themost
common free fatty acids found in hyperlipidemic animals [38,39]. Previ-
ous studies have shown that PA-induced oxidative stress contributes to
endothelial dysfunction and atherogenesis [40,41]. Our in vitro experi-
ments using HUVEC demonstrated that Ex-4 increased phosphorylation
of eNOSSer1177 and its upstream kinase, Aktser473, in response to VEGF
[42], which was affected by the presence of PA. This result corresponds
to previous studies that reported Akt/eNOS activation by Ex-4 [43,44].
Phosphorylation eNOS at Ser1177 increases NO production and medi-
ates endothelial function [20]. These results suggested that the antioxi-
dant property of GLP-1 attenuated endothelial dysfunction caused by
hyperlipidemia. In addition, Lina administration decreased ROS genera-
tion as determined by urinary excretion of 8-OHdG and the expression
of NADPH oxidase subunits Nox2 and p47phox in the aorta. The expres-
sion of Nox2 and p47phox is associated with vascular oxidative stress,
leading to the development of atherosclerosis. Especially, several stud-
ies have shown that Nox2-derived oxidative stress has a pathogenic
role in the functional changes of the arterial wall, including endothelial
cell function, in hyperlipidemia [45–47]. In fact, Lina-treated mice
showed lower expression of inﬂammatory molecules in the abdominal
aorta in our study. The result of in vitro experiments using HUVEC
which demonstrated inhibitory effect of EX-4 on inﬂammatory mole-
cule expression supported this in vivo data. These results suggest that
the antioxidative property of Lina, which is derived from elevated
GLP-1 level, contributes at least partially to the reduction of endothelial
damage and atherogenesis caused by hyperlipidemia. Recent evidence
suggests the cardioprotective effects of DPP-4 inhibitors independent
of incretins [48]. DPP-4 inhibitors attenuate degradation of stromal
cell-derived factor-1 and substance P as well as incretins, which may
contribute to vasoprotection at least in part [49]. Also, recent studies
suggest direct effects of DPP-4 inhibitors on vascular cells [48,50,51].
Further studies are needed to elucidate these effects of Lina, however
those studies will help clarify its vasoprotective effects and underlying
mechanisms.
In conclusion, our results demonstrated that Lina inhibited the
development atherosclerotic lesions in ApoE−/−mice, independent-
ly of blood glucose level. The beneﬁcial effect of Lina was associated
with attenuation of endothelial dysfunction, at least in part by a
reduction of oxidative stress. Taken together with the results of
previous studies, our results show that DPP-4 inhibitors have anti-
inﬂammatory effects on various cell types in the vasculature. Our
present study supports the results of recent studies that suggested
atheroprotective effects of DPP-4 inhibitors. These non-glycemic
properties of DPP-4 inhibitors may provide attractive therapeutic
options for atherosclerosis.Sources of funding
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